172@29@17@101!~!172@29@0@53!~!|news|tags|kiran-mazumdar-shaw.html|page-5|!~!news|moneycontrol|com!~!|controller|tag.php!~!is_mobile=false
kiran mazumdar shaw
Jump to
167 Results Found
  • Corporates carry clout, but Sebi stands firm: Sinha Jul 27, 2015 08:55 AM IST

    Corporates carry clout, but Sebi stands firm: Sinha

    At the same time, it is always "generous" and open to reasonable suggestions from the corporates, Sebi chief UK Sinha said, but regretted the fact that companies often come out with such "suggestions" after new regulations have already been framed.

  • Karnataka govt's Vision Group: Who's on the list, who's not Jul 24, 2015 09:33 PM IST

    Karnataka govt's Vision Group: Who's on the list, who's not

    What does a Chief Minister do when he runs out of ideas on how to boost investments in the state? He turns to the corporate big wigs who live in the state capital.

  • Biocon's Shaw says Sebi's insider trading norms 'draconian' Jul 24, 2015 08:56 PM IST

    Biocon's Shaw says Sebi's insider trading norms 'draconian'

    In a sharp criticism of regulator Sebi's new insider trading norms, industry leader and Biocon chief Kiran Mazumdar Shaw on Friday said these rules have "draconian intent" and will kill the ESOPs.

  • Biocon Q1 Net jumps 23% to Rs 126 crore Jul 23, 2015 09:49 PM IST

    Biocon Q1 Net jumps 23% to Rs 126 crore

    The company's net sales grew by 15 percent at Rs 857 crore for the period under review as compared to Rs 742 crore in the year-ago period, Biocon Ltd said in a statement.

  • Major progress in IPR policy, should roll out yr-end:Biocon Jul 22, 2015 03:00 PM IST

    Major progress in IPR policy, should roll out yr-end:Biocon

    Kiran Mazumdar Shaw, CMD, Biocon says there is a need to protect interest and disallow monopolies like big pharma or big companies/ corporates that want to invest and take advantage of the Indian market.

  • Biocon says may demerge Syngene in long run, post IPO Jul 16, 2015 10:17 PM IST

    Biocon says may demerge Syngene in long run, post IPO

    Drugmaker Biocon Ltd may hive off its contract research services arm, Syngene International Ltd, in the long run to help fund the development of its own products, it said, ahead of an initial public offering (IPO) of the unit.

  • Biocon sets price band for Syngene IPO at Rs 240-250/sh Jul 16, 2015 08:31 AM IST

    Biocon sets price band for Syngene IPO at Rs 240-250/sh

    The research arm of biotechnology major Biocon has received the approval from capital markets regulator SEBI for IPO in June after filing draft red herring prospectus (DRHP) through its lead merchant banker Axis Capital in April.

  • 4 Indians among world's 100 most powerful women: Forbes May 27, 2015 08:44 AM IST

    4 Indians among world's 100 most powerful women: Forbes

    SBI chief Arundhati Bhattacharya, ICICI bank head Chanda Kochhar, Biocon founder Kiran Mazumdar-Shaw and HT Media chairperson Shobhana Bhartia are among the world's 100 most powerful women, according to the Forbes' annual list which is topped by German chancellor Angela Merkel.

  • Rationalising products to become specialised player: Biocon Apr 30, 2015 12:10 PM IST

    Rationalising products to become specialised player: Biocon

    Biocon's Kiran Mazumdar Shaw said the company deliberately took a hit on its topline in order to rationalize products. Biocon is focusing towards being a specialized products player.

  • Biocon Q4 net jumps 78% to Rs 201 cr on Syngene shares sale Apr 30, 2015 09:06 AM IST

    Biocon Q4 net jumps 78% to Rs 201 cr on Syngene shares sale

    Biocon's fourth quarter profit after tax climbed 78 percent year-on-year to Rs 201 crore led by exceptional gains of Rs 105.06 crore (on account of sale of shares of Syngene).

  • See more upside for Biocon post Syngene listing: Phillipcap Apr 23, 2015 09:20 AM IST

    See more upside for Biocon post Syngene listing: Phillipcap

    Biocon plans to list its research arm Syngene and on Wednesday filed prospectus with the market regulator Sebi. It aims to raise around Rs 600 crore.

  • Syngene listing likely by July, may offload 10%: Biocon Apr 22, 2015 06:09 PM IST

    Syngene listing likely by July, may offload 10%: Biocon

    Biocon will be offloading at least 10 percent of Syngene equity as it needs funds to support some of its R&D programmes.

  • Biocon jumps 3% on Mexican nod for insulin glargine Apr 10, 2015 11:11 AM IST

    Biocon jumps 3% on Mexican nod for insulin glargine

    Shares of Biocon gained 3 percent intraday Friday on getting approval from the Mexican health authority for its insulin glargine.

  • Biocon gets approval for insulin Glargine in Mexico Apr 09, 2015 09:37 PM IST

    Biocon gets approval for insulin Glargine in Mexico

    The company's insulin Glargine has been approved by Cofepris, the Mexican health authority, through its Mexican partner PiSA Farmaceutica (PiSA), Biocon said in a statement.

  • Will get Syngene listed in FY16, to file DRHP in Q1: Biocon Apr 01, 2015 01:41 PM IST

    Will get Syngene listed in FY16, to file DRHP in Q1: Biocon

    Kiran Mazumdar Shaw, Chairperson and MD, Biocon also said that Syngene has good growth prospects and sound business plan and has a baseline valuation of Rs 3,800 crore.

  • Kiran Mazumdar-Shaw: A true Indian Business Icon Mar 31, 2015 04:19 PM IST

    Kiran Mazumdar-Shaw: A true Indian Business Icon

    Take a look at what has made Kiran Mazumdar-Shaw of Biocon a true Indian business icon.

  • FDA India scrutiny quality issue, no witch-hunt: Biocon CMD Mar 26, 2015 10:44 AM IST

    FDA India scrutiny quality issue, no witch-hunt: Biocon CMD

    Rubbishing concerns that the increasing FDA scrutiny of Indian pharma companieswas a case of "irrational clampdown", Biocon CMD Kiran Mazumdar-Shaw told CNBC-TV18 that the US regulator is mandating more stringent norms for companies across the world.

  • Union Budget 2015: Need to lower exemptions, moderate tax rates: Sunil Munjal Feb 28, 2015 10:59 AM IST

    Union Budget 2015: Need to lower exemptions, moderate tax rates: Sunil Munjal

    Sunil Munjal, joint managing director of Hero MotoCorp and senior member of CII expects finance minister Arun Jaitley to focus on manufacturing, infrastructure and logistics sectors.

  • Here's why Kiran Mazumdar-Shaw is named for IBI Jan 28, 2015 09:01 PM IST

    Here's why Kiran Mazumdar-Shaw is named for IBI

    Indian Business Icons (IBI) 2015, is a special initiative by CNBC-TV18 for celebrating 15 years of leadership. These names are now thrown open to public voting. The icon in focus is Kiran Mazumdar-Shaw.

  • Biocon says to take Syngene unit public Jan 23, 2015 09:14 AM IST

    Biocon says to take Syngene unit public

    Biocon had previously said it planned to list Syngene but had not given a timeline. Late on Thursday, it said its board had approved starting the process of listing and hiring merchant bankers to sell 10-15 percent from Biocon's majority stake in the unit in the public offer.

  • India-US CEO forum recast; Cyrus Mistry to be co-chair Jan 05, 2015 10:12 PM IST

    India-US CEO forum recast; Cyrus Mistry to be co-chair

    Vishal Sikka, Infosys' CEO; Arundhati Bhattacharya, chairperson, SBI; and B Prasada Rao, executive chairman, BHEL, are the new entrants.

  • Need near-term reforms urgently to boost eco growth: Biocon Dec 19, 2014 12:27 PM IST

    Need near-term reforms urgently to boost eco growth: Biocon

    Kiran Mazumdar Shaw said economy needs some urgent boost. Government must come out with short-term measures that will accelerate economic growth.

  • Software sector is largest creator of jobs: Narayana Murthy Nov 26, 2014 07:17 PM IST

    Software sector is largest creator of jobs: Narayana Murthy

    NR Narayana Murthy said that software industry has overtaken PSUs as biggest job creator in the country with about 32 lakh-strong workforce and further addition of two lakh new jobs a year.

  • Bhattacharya most powerful Indian woman in biz: Fortune Nov 09, 2014 03:23 PM IST

    Bhattacharya most powerful Indian woman in biz: Fortune

    ICICI Bank's Chanda Kochhar and Shikha Sharma of Axis Bank follow Bhattacharya at the second and the third place respectively.

  • Biocon launches second-generation INSUpen EZ Oct 29, 2014 03:02 PM IST

    Biocon launches second-generation INSUpen EZ

    Biocon has launched INSUpen EZ, a second-generation insulin-delivery pen device, developed by Germany‘s Haselmeier. “This is a low-cost pen, which will help us penetrate the market in a bigger way,” CMD Kiran Mazumdar-Shaw told CNBC-TV18‘s Ekta Batra and Nigel D‘Souza.

Sections